Plasma and Cellular Forms of Fibronectin as Prognostic Markers in Sepsis.
Journal
Mediators of inflammation
ISSN: 1466-1861
Titre abrégé: Mediators Inflamm
Pays: United States
ID NLM: 9209001
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
04
2020
revised:
22
06
2020
accepted:
22
07
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
17
7
2021
Statut:
epublish
Résumé
There is a pressing need for specific prognostic markers that could be used to monitor the severity of sepsis. The aims of our study were to investigate changes in the expression of different molecular forms of fibronectin in sepsis and to assess their relationship to the clinical severity and mortality of patients. The baseline pFN concentration of patients with sepsis was significantly lower than in the control (133.0 mg/L vs. 231.2 mg/L) ( The study showed that in sepsis, changes in plasmatic and cellular form of fibronectin were associated with the severity of sepsis and may be useful predictors of outcome.
Sections du résumé
BACKGROUND
BACKGROUND
There is a pressing need for specific prognostic markers that could be used to monitor the severity of sepsis. The aims of our study were to investigate changes in the expression of different molecular forms of fibronectin in sepsis and to assess their relationship to the clinical severity and mortality of patients.
RESULTS
RESULTS
The baseline pFN concentration of patients with sepsis was significantly lower than in the control (133.0 mg/L vs. 231.2 mg/L) (
CONCLUSION
CONCLUSIONS
The study showed that in sepsis, changes in plasmatic and cellular form of fibronectin were associated with the severity of sepsis and may be useful predictors of outcome.
Identifiants
pubmed: 32801997
doi: 10.1155/2020/8364247
pmc: PMC7416265
doi:
Substances chimiques
Fibronectins
0
Fibrin
9001-31-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8364247Informations de copyright
Copyright © 2020 Anna Lemańska-Perek et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Int J Infect Dis. 2004 Jul;8(4):236-43
pubmed: 15234328
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Clin Chem Lab Med. 2006;44(1):37-42
pubmed: 16375583
J Leukoc Biol. 2008 Mar;83(3):536-45
pubmed: 18032692
J Cell Biol. 1994 Dec;127(6 Pt 2):2037-48
pubmed: 7806580
Atherosclerosis. 2007 Nov;195(1):e83-91
pubmed: 17416372
Crit Care Resusc. 2012 Sep;14(3):211-5
pubmed: 22963216
Blood Coagul Fibrinolysis. 2017 Mar;28(2):163-170
pubmed: 27254441
J Immunoassay Immunochem. 2014;35(4):412-27
pubmed: 24547768
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
J Pathol. 2008 Sep;216(1):1-14
pubmed: 18680111
J Thromb Haemost. 2007 Mar;5(3):604-6
pubmed: 17096704
Nat Med. 2001 Mar;7(3):324-30
pubmed: 11231631
Crit Care Resusc. 2013 Dec;15(4):279-86
pubmed: 24289509
J Cell Sci. 2002 Oct 15;115(Pt 20):3861-3
pubmed: 12244123
Chest. 2005 Oct;128(4):2864-75
pubmed: 16236964
Fibrogenesis Tissue Repair. 2011 Sep 16;4:21
pubmed: 21923916
Clin Biochem. 2013 Jun;46(9):787-94
pubmed: 23518314
Shock. 2000 Jun;13(6):492-6
pubmed: 10847638
Neoplasia. 2013 Aug;15(8):925-38
pubmed: 23908593
Am J Respir Crit Care Med. 2008 Mar 15;177(6):638-45
pubmed: 18096707
Mol Biol Cell. 2006 Dec;17(12):5198-210
pubmed: 17021255
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
Infect Immun. 2011 Jun;79(6):2215-23
pubmed: 21422173
J Clin Microbiol. 2014 Nov;52(11):4063-6
pubmed: 25187630
Thromb Res. 2017 Jan;149:38-44
pubmed: 27886531
Inflammation. 2016 Jun;39(3):1059-68
pubmed: 27022744
Cancer Res. 2007 Nov 15;67(22):10948-57
pubmed: 18006840
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Sci Rep. 2016 Nov 29;6:37965
pubmed: 27897258
Open Forum Infect Dis. 2018 Nov 19;5(12):ofy313
pubmed: 30555852
Dis Markers. 2016;2016:3695454
pubmed: 27635109
EMBO Mol Med. 2012 Jul;4(7):564-76
pubmed: 22514136
Clin Biochem. 2009 May;42(7-8):654-61
pubmed: 19161998